Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karoline Sonneck, MD, Alexander Gruze, Puchit Samorapoompichit, MD, Karl J. Aichberger, MD, Francis Y. Lee, PhD, Paul W. Manley, PhD, Doriano Fabbro, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 526.

https://doi.org/10.1182/blood.V108.11.526.526

Published: 2006

Journal Articles

Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.

Michael Kneidinger, MD, Peter Valent, MD, Karoline V. Gleixner, MD, Stefan Florian, MD, Alexandra Boehm, MD, Karoline Sonneck, MD, Margit Weghofer, Christian Lupinek, Susanne Vrtala, MD, Anja Vales, MD, Rudolf Valenta, MD, Giulio Superti-Furga, PhD, Francis Y. Lee, PhD

Blood (2006) 108 (11): 1365.

https://doi.org/10.1182/blood.V108.11.1365.1365

Published: 2006

Journal Articles

Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis.

Karoline V. Gleixner, MD, Mayerhofer Matthias, MD, Anja Vales, MD, Alexander Gruze, Michael Kneidinger, MD, Gregor Hoermann, Maria T. Krauth, MD, Rudin Kondo, MD, Karoline Sonneck, MD, Puchit Samorapoompichit, MD, Eva Lackner, MD, Khaled Greish, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Christoph C. Zielinski, MD, Hiroshi Maeda, MD, Peter Valent, MD

Blood (2006) 108 (11): 4323.

https://doi.org/10.1182/blood.V108.11.4323.4323

Published: 2006

Journal Articles

Detection of Activated STAT5 in the Cytoplasm of Neoplastic Cells in Patients with AML, CML, and Systemic Mastocytosis.

Karoline Sonneck, MD, Richard Fritz, MSc, Leonhard Muellauer, MD, Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Stefan Florian, MD, Marc Kerenyi, MSc, Wolfgang R. Sperr, MD, Christian Sillaber, MD, Richard Moriggl, PhD, Peter Valent, MD

Blood (2006) 108 (11): 2305.

https://doi.org/10.1182/blood.V108.11.2305.2305

Published: 2006

Journal Articles

PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karl J. Aichberger, MD, Sophia Derdak, PhD, Karoline Sonneck, MD, Alexandra Boehm, MD, Puchit Samorapoompichit, MD, Alexander Gruze, Winfried Pickl, Paul Manley, Doriano Fabbro, Christian Sillaber, Peter Valent

Blood (2005) 106 (11): 3523.

https://doi.org/10.1182/blood.V106.11.3523.3523

Published: 2005

Journal Articles

Detection of Activated STAT5 in Neoplastic Mast Cells in Patients with Systemic Mastocytosis: Role of c-kit D816V.

Karoline Sonneck, MD, Matthias Mayerhofer, MD, Karoline V. Gleixner, Marc Kerenyi, Maria-Theresa Krauth, MD, Richard Fritz, Christian Sillaber, MD, Richard Moriggl, Peter Valent, MD

Blood (2005) 106 (11): 3515.

https://doi.org/10.1182/blood.V106.11.3515.3515

Published: 2005

Journal Articles

Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.

Alexandra Boehm, MD, Stefan Florian, MD, Karoline Gleixner, Karoline Sonneck, MD, Karl J. Aichberger, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2005) 106 (11): 3518.

https://doi.org/10.1182/blood.V106.11.3518.3518

Published: 2005

Journal Articles

Phenotyping of Neoplastic (CD34 + /CD38 − /CD123 + ) Stem Cells in Myeloid Malignancies Reveals Expression of Multiple Molecular Targets.

Stefan Florian, MD, Karoline Sonneck, MD, Alexander W. Hauswirth, MD, Maria-Theresa Krauth, MD, Wolfgang R. Sperr, MD, Peter Valent, MD

Blood (2005) 106 (11): 1381.

https://doi.org/10.1182/blood.V106.11.1381.1381

Published: 2005

Journal Articles

Targeting of mTOR in AML Is Associated with Decreased Growth of Leukemic Cells and Downregulation of VEGF.

Alexandra Boehm, MD, Karl J. Aichberger, MD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Puchit Samorapoompichit, MD, Christian Sillaber, MD, Stefan Florian, Karoline Sonneck, MD, Wolfgang R. Sperr, MD, Peter Valent, MD

Blood (2004) 104 (11): 2544.

https://doi.org/10.1182/blood.V104.11.2544.2544

Published: 2004

Journal Articles

Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML.

Karl J. Aichberger, MD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Hans Skvara, MD, Stefan Florian, MD, Karoline Sonneck, MD, Cahit Akgul, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Brett P. Monia, PhD, Richard Moriggl, PhD, Peter Valent, MD, Christian Sillaber, MD

Blood (2004) 104 (11): 2972.

https://doi.org/10.1182/blood.V104.11.2972.2972

Published: 2004

NARROW

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.

Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis.

Detection of Activated STAT5 in the Cytoplasm of Neoplastic Cells in Patients with AML, CML, and Systemic Mastocytosis.

PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions.

Detection of Activated STAT5 in Neoplastic Mast Cells in Patients with Systemic Mastocytosis: Role of c-kit D816V.

Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.

Phenotyping of Neoplastic (CD34 + /CD38 − /CD123 + ) Stem Cells in Myeloid Malignancies Reveals Expression of Multiple Molecular Targets.

Targeting of mTOR in AML Is Associated with Decreased Growth of Leukemic Cells and Downregulation of VEGF.

Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only